Novo Nordisk says the Wegovy pill saw the fastest take-up in weight-loss drug history.
MarketWatch
Last updated: May 6, 2026
Novo Nordisk is experiencing significant demand for its GLP-1 medications, Ozempic and Wegovy, as indicated by a substantial increase in weekly prescriptions. This surge in demand highlights the growing popularity and therapeutic interest in these weight-loss and diabetes management drugs. The company's production and distribution are under pressure to meet this escalating need.
- Novo Nordisk reported an increase of 200,000 weekly prescriptions for its GLP-1 drugs, Ozempic and Wegovy. These medications, based on semaglutide, are prefilled pens for self-injection. The demand for these drugs has significantly outpaced supply, leading to potential shortages. The article implies a widespread and growing adoption of these treatments for both diabetes management and weight loss, driving the high prescription numbers. The visual context is a medicine distributor displaying these popular medications. The increasing weekly prescriptions reflect a strong market trend and therapeutic preference.
